Williams Laura A sold $490K of ARDX

Williams Laura A (Chief Patient Officer) sold 81,898 shares of ARDELYX, INC. (ARDX) at $5.99 ($0.49M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Laura A
Published Jun 22, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
medium confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the company’s Chief Patient Officer under a 10b5-1 plan.

02

Market read

This provides a transparent datapoint on insider selling, but the 10b5-1 structure limits interpretability for trading decisions.

03

What to watch

Traders may over-weight insider sales; the more actionable signal would be subsequent buys, changes in guidance, or clinical/regulatory updates rather than routine Form 4 activity.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date (2026-06-22) for ARDX insider-sale disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for ARDELYX, INC. (ARDX).

Company-level read

Ticker impact

$ARDXNeutralMedium confidence
Context

SEC Form 4 shows ARDX Chief Patient Officer Laura Williams sold 81,898 shares for about $490.5K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale by an officer with a pre-arranged 10b5-1 plan, which reduces the informational content versus discretionary selling.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be largely mechanical and not a bearish signal at all.

Key entities

  • ARDX

    Ardelyx, Inc.; subject of the Form 4 insider transaction disclosure.

  • Laura Williams

    Chief Patient Officer who sold 81,898 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.